Neogen Chemicals Limited has approved a ₹245 crore business transfer agreement to consolidate its electrolyte salt manufacturing operations. The move aims to enhance the group’s battery materials strategy by centralizing specialized capabilities within its step-down subsidiary, Neogen Morita New Materials Limited (NML).

The transaction involves the sale of an undertaking by wholly owned subsidiary Neogen Ionics Limited (NIL) to NML. The Board of Directors of both entities approved the Business Transfer Agreement (BTA) on August 31, 2026. Shareholders of NIL also granted necessary approvals during a meeting held on the same date. The transfer is structured on a going concern basis, subject to regulatory approvals and completion of condition precedents outlined in the agreement.

Transaction Structure and Timeline

The BTA mandates that the undertaking be transferred from NIL to NML by March 31, 2027. The consideration of ₹245 crore represents the net value of assets after deducting relevant liabilities. As this is a transaction between wholly owned subsidiaries, it qualifies as a related party transaction but is exempt from specific approval requirements under Regulation 23 of the SEBI Listing Regulations and Section 188 of the Companies Act, 2013.

Financial Impact and Rationale

The strategic move aims to consolidate Neogen’s Electrolyte Salt (LiPF6) businesses under NML. NIL, incorporated in March 2023, reported a turnover of ₹35.97 crore for the fiscal year ended March 31, 2026. In contrast, NML, incorporated in July 2025, reported nil turnover for the same period.

Despite contributing zero percent to the consolidated revenue of the parent company in FY26, the undertaking being transferred holds significant balance sheet weight. Its net worth stood at ₹155.52 crore as of March 31, 2026, representing 19.05% of Neogen Chemicals’ consolidated net worth and 57.36% of NIL’s consolidated net worth.

What the Numbers Show

The divergence between NIL’s revenue contribution and its net worth contribution highlights the capital-intensive nature of the electrolyte salt assets. While the unit generated no consolidated revenue impact in FY26, it commands nearly one-fifth of the group’s total net worth. This suggests the transferred assets are primarily fixed or inventory-based investments rather than high-turnover trading books, aligning with the strategic goal of centralizing specialized manufacturing capabilities within NML.

Neogen Chemicals disclosed an off-market gift of 354 equity shares by Mrs. Heena Hitesh Reshamwala to Mr. Viren Reshamwala on August 25, 2026. The transaction, valued at nil consideration, was reported under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015.

Mrs. Reshamwala, the spouse of Mr. Hitesh Reshamwala, transferred the shares to Mr. Viren Reshamwala, who is related to Mr. Hitesh Reshamwala. The transfer reduced Mrs. Reshamwala’s holding from 6,173 shares (approximately 0.02% of paid-up capital) to 5,819 shares. Concurrently, Mr. Viren Reshamwala’s holding increased from 500 shares to 854 shares.

Transaction Details

The pre-clearance for the transaction was sought between August 19, 2026, and August 27, 2026. The company confirmed that no unpublished price-sensitive information was in possession during the trade.

The disclosure was submitted within two days of the transaction execution, adhering to regulatory timelines. No derivatives trading was reported alongside this equity transfer.